Cellular Senescence Signatures for Abdominal Aortic Aneurysm: Evidence and Implications

Study Background and Research Question

Abdominal aortic aneurysm (AAA) is a life-threatening vascular disease, characterized by progressive dilation of the abdominal aorta and a high risk of rupture in advanced stages. Despite the prevalence of AAA among older adults, early detection remains challenging due to the insidious and asymptomatic nature of disease progression. Conventional diagnostic modalities, such as imaging, are effective for monitoring aneurysm size but have notable limitations: they often miss early molecular changes, are not universally accessible, and carry risks associated with radiation or contrast exposure. Thus, there is an urgent need for noninvasive, molecular biomarkers that could enable timely diagnosis and intervention before catastrophic rupture occurs.

Recent studies, including those on Angiotensin II in Vascular Pathobiology, have highlighted the role of cellular senescence in vascular remodeling and AAA pathogenesis. However, the precise molecular signatures and their translational potential for diagnosis and therapy have remained underexplored.

Key Innovation from the Reference Study

The open-access paper by Zhang et al. (Journal of Cellular and Molecular Medicine, 2025) brings a distinctive innovation to the field by systematically interrogating senescence-related genes (SRGs) as diagnostic and potentially therapeutic targets in AAA. By integrating large-scale transcriptomic data with advanced machine learning, the authors identify ETS1 and ITPR3 as senescence-associated candidate biomarkers, validated across human cohorts and animal models. This work represents a significant advance in translating molecular aging signatures into actionable diagnostic tools for vascular disease.

Methods and Experimental Design Insights

The research employed a multi-phase workflow:

• Data Mining and DEG Identification: Transcriptomic data from the GSE57691 cohort were analyzed to identify 429 differentially expressed genes (DEGs) between AAA and control tissues.
• Senescence Gene Intersection: A curated list of 867 senescence-related genes (SRGs) was intersected with the DEGs to yield 19 differentially expressed senescence-related genes (DESRGs).
• Machine Learning Hub Gene Selection: Three complementary algorithms—LASSO regression, support vector machine recursive feature elimination (SVM-RFE), and random forest—were used to prioritize hub DESRGs based on diagnostic potential.
• Validation in Independent Cohorts: Expression differences for selected genes (BTG2, ETS1, ID1, ITPR3) were validated in additional human datasets and serum samples, as well as in mouse models of AAA.
• Single-Cell RNA Sequencing: The role of senescent endothelial cells was further characterized using scRNA-seq, and the association of ETS1/ITPR3 with these cells was confirmed via Western blot, immunofluorescence, and RT-qPCR.

Diagnostic performance was evaluated using receiver operating characteristic (ROC) analysis, reinforcing the translational relevance of the findings.

Core Findings and Why They Matter

The study’s central finding is the identification of ETS1 and ITPR3 as robust, senescence-related diagnostic biomarkers for AAA. Both genes exhibited strong differential expression in AAA versus controls, with ROC analysis demonstrating high diagnostic accuracy across different disease stages. Notably, the expression patterns were consistent in human serum and animal models, suggesting broad applicability.

Single-cell RNA sequencing revealed that senescent endothelial cells, marked by upregulation of ETS1 and ITPR3, are pivotal contributors to AAA progression. This mechanistic insight connects cellular aging processes to aneurysm development, supporting a paradigm in which vascular senescence is both a driver and a marker of disease. The identification of these markers lays a foundation for nonimaging-based, minimally invasive diagnostics and may inform future therapeutic strategies targeting senescent cell populations in vascular disease.

Comparison with Existing Internal Articles

Internal reviews, such as Angiotensin II: Mechanistic Insight and Strategic Guidance, provide a complementary perspective by detailing the role of Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) as a potent vasopressor and GPCR agonist in vascular remodeling and AAA models. These resources underscore how Angiotensin II-induced vascular smooth muscle cell hypertrophy and inflammatory signaling intersect with senescence pathways, echoing the reference study’s focus on the molecular interplay between aging and aneurysm formation. Another article, Solving Laboratory Challenges in Hypertension and Fibrosis Research, emphasizes the reproducibility of preclinical AAA models using Angiotensin II, highlighting experimental parameters relevant for validating senescence signatures in vivo.

Whereas the internal articles explore the mechanistic landscape of Angiotensin II in vascular pathology and hypertension mechanism study, the reference study uniquely advances the field by pinpointing specific senescence genes for diagnostic application and cross-validating them in human and animal models.

Limitations and Transferability

Despite its strengths, the study has several limitations. The reliance on transcriptomic datasets may introduce biases related to sample heterogeneity and platform variability. Although diagnostic performance was validated in multiple cohorts, further prospective studies are required to establish utility in broader, more diverse populations. The animal model findings, while supportive, may not fully recapitulate human pathophysiology, so translational caution is warranted.

Moreover, while ETS1 and ITPR3 are promising as diagnostic biomarkers, their functional roles in aneurysm progression—and their suitability as therapeutic targets—require deeper mechanistic elucidation. The potential for clinical adoption will depend on developing accessible assays and integrating these biomarkers into current care pathways.

Protocol Parameters

• Induction of AAA in animal models: Angiotensin II is typically administered via subcutaneous minipumps at 500–1000 ng/min/kg for up to 28 days to induce AAA and study vascular remodeling, as outlined in the Angiotensin II product documentation.
• Cell culture stimulation for mechanistic studies: Treat vascular smooth muscle cells or endothelial cells with 100 nM Angiotensin II for 4 hours to activate NADH/NADPH oxidases and downstream senescence or hypertrophy pathways.
• Sample collection and validation: Collect tissue and serum samples at defined endpoints for qPCR, Western blot, and immunofluorescence analysis targeting ETS1, ITPR3, and other candidate markers.

Research Support Resources

For researchers aiming to replicate or extend these findings, Angiotensin II (SKU A1042) from APExBIO is widely used to establish preclinical AAA models and probe the molecular mechanisms underlying vascular smooth muscle cell hypertrophy and senescence. Its well-characterized pharmacological profile and solubility standards facilitate reproducible experimental designs. For additional mechanistic context or troubleshooting, see the in-depth reviews on Angiotensin II signaling and vascular disease processes available in the internal literature cited above.